Purespring Therapeutics
Latest round
- Series B
Last raised
- Oct 2024
Total raised
- $165M
Investors
- 5
About Purespring Therapeutics
Founded in 2020 and based in London, UK, Purespring Therapeutics Limited, formerly known as SYNCONA COLLABORATION (S) LIMITED, operates as a provider of gene therapies targeting podocytes to healthcare institutions and medical researchers working on kidney disease treatments. Purespring Therapeutics offers gene therapy treatments targeting podocytes for glomerular kidney diseases. Moreover, the firm's pipeline includes PS-002 for IgA nephropathy, therapies for monogenic podocyte disorders, and glomerular basal membrane deficiencies. Additionally, the company also develops platforms for renal gene therapies and collaborates on kidney disease research.
Who invested in Purespring Therapeutics
5 investors across 2 rounds
See all investors in Purespring Therapeutics
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Questions about Purespring Therapeutics
Who invested in Purespring Therapeutics?
Purespring Therapeutics has 5 investors on record across 2 venture rounds. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Purespring Therapeutics raised?
Purespring Therapeutics has raised 2 venture rounds. Sign up free to see how much each round raised and the total.
When did Purespring Therapeutics last raise money?
Purespring Therapeutics's most recent round on record is a Series B, in Oct 2024.
What does Purespring Therapeutics do?
Founded in 2020 and based in London, UK, Purespring Therapeutics Limited, formerly known as SYNCONA COLLABORATION (S) LIMITED, operates as a provider of gene therapies targeting podocytes to healthcare institutions and medical researchers working on kidney disease treatments.
Where is Purespring Therapeutics headquartered?
Purespring Therapeutics is headquartered in London, UK.
Which VCs invest in companies like Purespring Therapeutics?
Among active investors with capital left to deploy, Index Ventures, Forbion, European Investment Bank and Generation Investment Management back biotechnology companies at Purespring Therapeutics's stage. Their profiles are linked below.
VCs backing biotechnology startups at Series B
Raising like Purespring Therapeutics? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.